Highlight Articles

NRx Pharmaceuticals Presents Evidence ZYESAMI™ (aviptadil) Helps Prevent “Cytokine Storm” in Patients with COVID-19

Sudden Rise in Inflammatory Cytokines (IL-6) Associated with Death in COVID-19 and Other Forms of Acute Respiratory Distress SyndromeData from Randomized Phase 2b/3 Trial Shows Patients Treated with ZYESAMI™ are […]

Continue Reading
NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia

More than One Thousand New Cases of COVID-19 Diagnosed Every Day in Georgia, With Increasing Detection of the Delta VariantAssociation of Georgian Physicians Unanimously Supports Regulatory DecisionTraining of Georgian Doctors […]

Continue Reading